赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNY 赛诺菲安万特

已收盘 11-18 16:00:00 EST

48.51

+0.54

+1.13%

盘后47.04

-1.47-3.03%

19:50 EST

最高48.67	最低47.94	成交量261.39万
今开47.99	昨收47.97	日振幅1.52%
总市值1,216亿	流通市值1,070亿	总股本25.07亿
成交额1.27亿	换手率0.12%	流通股本22.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNY","market":"US","secType":"STK","nameCN":"赛诺菲安万特","latestPrice":48.51,"timestamp":1731963600000,"preClose":47.97,"halted":0,"volume":2613945,"hourTrading":{"tag":"盘后","latestPrice":47.04,"preClose":48.51,"latestTime":"19:50 EST","volume":667487,"amount":32379145.4435,"timestamp":1731977440390},"delay":0,"floatShares":2205617416,"shares":2507185442,"eps":2.001617,"marketStatus":"已收盘","marketStatusCode":5,"change":0.54,"latestTime":"11-18 16:00:00 EST","open":47.99,"high":48.67,"low":47.94,"amount":126571360.002825,"amplitude":0.015218,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.001617,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732006800000},"adr":1,"listingDate":1025496000000,"adjPreClose":47.97,"adrRate":0.5,"dividendRate":0.041858,"preHourTrading":{"tag":"盘前","latestPrice":47.99,"preClose":47.97,"latestTime":"09:29 EST","volume":6084,"amount":291985.536492,"timestamp":1731940170027},"postHourTrading":{"tag":"盘后","latestPrice":47.04,"preClose":48.51,"latestTime":"19:50 EST","volume":667487,"amount":32379145.4435,"timestamp":1731977440390},"volumeRatio":0.999647,"impliedVol":0.2655,"impliedVolPercentile":0.4502},"requestUrl":"/m/hq/s/SNY","defaultTab":"news","newsList":[{"id":"2483597453","title":"BUZZ-特朗普任命肯尼迪为卫生机构负责人，疫苗制造商和包装食品公司业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2483597453","media":"路透中文","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483597453?lang=zh_cn&edition=full","pubTime":"2024-11-15 06:41","pubTimestamp":1731624112,"startTime":"0","endTime":"0","summary":"11月14日 - ** 由于美国当选总统特朗普选择小罗伯特-肯尼迪领导卫生与公众服务部，疫苗生产商的股票在周四交易时段结束时暴跌。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8b50228a679c44f870e44bbf889089f6","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4T3ML222:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0265550946.USD","IE00B19Z3B42.SGD","LU1934455277.USD","MRK","LU0006061336.USD","PFE","GSK.UK","LU2361044865.SGD","MRNA","SGXZ57979304.SGD","LU0575583348.USD","IE00BWDBJ516.SGD","LU1066051225.USD","LU1066053197.SGD","LU1699723380.USD","LU1989772840.SGD","LU1057294990.SGD","BK4585","BK4007","LU0965508806.USD","LU1481599808.USD","LU0868494617.USD","LU0971552673.USD","IE00B4R5TH58.HKD","IE00B19Z3581.USD","LU1035777561.USD","LU1917777945.USD","LU0006306889.USD","IE0002270589.USD","IE00B1BXHZ80.USD","LU1929549753.HKD","LU0109981661.USD","SYY","SNY","KHC","BNTX","LU1037948541.HKD","LU1098665638.USD","BK4534","LU0985481810.HKD","IE00BJT1NW94.SGD","LU1015430645.USD","LU0965509101.SGD","LU1989772923.USD","SG9999011175.SGD","IE00BFTCPJ56.SGD","LU1645745479.HKD","SG9999014559.SGD","PEP","LU1941712264.USD"],"gpt_icon":1},{"id":"2483443280","title":"赛诺菲(SNY.US)新药lunsekimig注射液在华再次获批临床试验 拟用于治疗哮喘","url":"https://stock-news.laohu8.com/highlight/detail?id=2483443280","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483443280?lang=zh_cn&edition=full","pubTime":"2024-11-13 14:02","pubTimestamp":1731477773,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国国家药监局药品审评中心官网近日公示，赛诺菲申报的1类新药lunsekimig注射液获得一项新的临床试验默示许可，拟开发用于治疗成人高风险哮喘。该产品此前已经在中国获批IND，针对适应症为成人中重度哮喘。根据中国药物临床试验与信息公示平台官网，赛诺菲正在开展两项针对中重度哮喘成人受试者的2期临床研究，用于探索lunsekimig的剂量范围，以及评价该产品的长期安全性和疗效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1583","BK4588","BK1576","BK4007","03347","BK1141","IE00BFXG1179.USD","SNY"],"gpt_icon":0},{"id":"2479440216","title":"赛诺菲(SNY.O)CEO：医疗不平等是我们面临的最重大挑战，这并不局限于发展中国家。","url":"https://stock-news.laohu8.com/highlight/detail?id=2479440216","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479440216?lang=zh_cn&edition=full","pubTime":"2024-10-29 15:24","pubTimestamp":1730186669,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["0O59.UK","SNY","IE00BFXG1179.USD","BK5011","BK4007","BK4585","BK4588","159891"],"gpt_icon":0},{"id":"2478871959","title":"金十数据整理：每日美股市场要闻速递（10月25日 周五）","url":"https://stock-news.laohu8.com/highlight/detail?id=2478871959","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478871959?lang=zh_cn&edition=full","pubTime":"2024-10-25 21:09","pubTimestamp":1729861744,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE0004086264.USD","VALE","SNY","IE00BYQQ9H92.USD","IE00B4YYXB79.USD","MCD","BK4548","LU0640476718.USD","0O59.UK","LU0029864427.USD","BK5011","IE000YTNTUN2.SGD","LU0109391861.USD","LU0256859116.SGD","BK4209","LU2357305700.SGD","BK4585","LU0130518102.USD","LU0456855351.SGD","LU1585245621.USD","LU0942090050.USD","BK4514","IE00BLSP4239.USD","IE00BN29S564.USD","LU0106261372.USD","LU0109392836.USD","BK4006","LU0097036916.USD","IE00B5949003.HKD","IE00BHPRN162.USD","IE00BZ1G4Q59.USD","IE0034235303.USD","IE00BJJMRY28.SGD","BK4507","LU0198837287.USD","IE000KEQY171.SGD","LU0068578508.USD","LU1548497426.USD","LU0127658192.USD","IE00BDRTCR15.USD","BK4553","FFIE","IE00BWXC8680.SGD","BK4587","IE00B4JS1V06.HKD","LU0053666078.USD","LU0086394185.USD"],"gpt_icon":0},{"id":"2478372606","title":"赛诺菲安万特(SNY)盘前涨2.75% Q3净利润同比增长约11.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478372606","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478372606?lang=zh_cn&edition=full","pubTime":"2024-10-25 17:17","pubTimestamp":1729847862,"startTime":"0","endTime":"0","summary":"金吾财讯 | 赛诺菲安万特(SNY)盘前涨2.75%，截至发稿，报53.48美元。消息面上，公司公布第三季度财报。期内，净利润28.2亿欧元，去年同期为25.3亿欧元，同比增长约11.5%，主要得益于季节性疫苗需求的增长和其重磅药物Dupixent的强劲表现而上升。期内，每股收益2.86欧元，超出分析师预期，主要得益于流感和呼吸道合胞病毒疫苗销售的提前。期内，销售额134.4亿欧元，同比增长12%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"281287","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"gpt_icon":0},{"id":"2478677070","title":"赛诺菲安万特(SNY)Q3净利润同比增长约11.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478677070","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478677070?lang=zh_cn&edition=full","pubTime":"2024-10-25 16:29","pubTimestamp":1729844971,"startTime":"0","endTime":"0","summary":"金吾财讯 | 赛诺菲安万特(SNY)公布第三季度财报。期内，净利润28.2亿欧元，去年同期为25.3亿欧元，同比增长约11.5%，主要得益于季节性疫苗需求的增长和其重磅药物Dupixent的强劲表现而上升。期内，每股收益2.86欧元，超出分析师预期，主要得益于流感和呼吸道合胞病毒疫苗销售的提前。期内，销售额134.4亿欧元，同比增长12%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/NDE1ZTkwNWY0MmUyYmYxZmRmMGIxMjc1MDdiMzUxMjY5MjE4NTQ3Mw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NDE1ZTkwNWY0MmUyYmYxZmRmMGIxMjc1MDdiMzUxMjY5MjE4NTQ3Mw==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"281281","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY"],"gpt_icon":0},{"id":"2478824673","title":"赛诺菲Q3利润大增，上调年度利润预测并加速药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2478824673","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478824673?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:10","pubTimestamp":1729840253,"startTime":"0","endTime":"0","summary":"法国制药巨头赛诺菲赛诺菲的第三季度利润因季节性疫苗需求的增长和其重磅药物Dupixent的强劲表现而上升。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199624.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛诺菲Q3利润大增，上调年度利润预测并加速药物开发","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["0O59.UK","SNY","BK5011","BK4588","IE00BFXG1179.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2478620031","title":"交易员：赛诺菲(SNY.O)第三季度业绩好于预期，股价料上涨1%-3.5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2478620031","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478620031?lang=zh_cn&edition=full","pubTime":"2024-10-25 14:39","pubTimestamp":1729838359,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["SNY","BK4007","0O59.UK","BK4588","BK4585","IE00BFXG1179.USD","BK5011"],"gpt_icon":0},{"id":"2478666033","title":"赛诺菲安万特盘中异动 临近收盘股价大跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478666033","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478666033?lang=zh_cn&edition=full","pubTime":"2024-10-25 03:55","pubTimestamp":1729799719,"startTime":"0","endTime":"0","summary":"北京时间2024年10月25日03时55分，赛诺菲安万特股票出现异动，股价快速下跌5.14%。截至发稿，该股报50.17美元/股，成交量252.071万股，换手率0.10%，振幅5.52%。赛诺菲安万特股票所在的制药行业中，整体跌幅为0.78%。赛诺菲安万特公司简介：赛诺菲开发和销售专注于肿瘤学、免疫学、心血管疾病、糖尿病和疫苗的药物。该公司总收入的大约 40% 来自美国，25% 来自欧洲，其余大部分收入来自新兴市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102503551998e3e511&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102503551998e3e511&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4007","SNY","BK4588","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2477378608","title":"成功竞购赛诺菲(SNY.US)消费者健康业务后 CD&R面临增长潜力挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2477378608","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477378608?lang=zh_cn&edition=full","pubTime":"2024-10-23 14:55","pubTimestamp":1729666500,"startTime":"0","endTime":"0","summary":"智通财经注意到，在击败最后的竞争对手 PAI Partners 后，Clayton Dubilier & Rice LLC 最终赢得了从赛诺菲剥离出来的 Opella 消费者保健业务的拍卖。赛诺菲表示，拟议中的交易仍有待最终协议和法定批准，预计最早将于2025年第二季度完成。在这笔交易中，CD&R将获得80亿欧元股权中的一半。好消息是，CD&R在与现有所有者合作进行拆分方面拥有丰富的经验。尽管 CD&R 在第一轮政治热潮中没有受到打击，但仍有可能出现更多冲突。现在 CD&R 有机会证明他们如此保守是错误的了。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4588","SNY","IE00BFXG1179.USD","BK4585"],"gpt_icon":0},{"id":"2477889423","title":"赛诺菲确认与CD&R就出售消费保健业务Opella进入独家谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2477889423","media":"智通财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477889423?lang=zh_cn&edition=full","pubTime":"2024-10-21 15:32","pubTimestamp":1729495940,"startTime":"0","endTime":"0","summary":"智通财经获悉，赛诺菲周一表示，已就将其消费者保健业务Opella 50%的控股权出售给美国私募股权公司Clayton Dubilier & Rice进入排他性谈判。赛诺菲表示，拟议中的交易仍有待最终协议和法定批准，预计最早将于2025年第二季度完成。他补充称，尽管赛诺菲参与Opella项目的时间还没有确定，但“我们预计将长期参与并保持合作关系”。赛诺菲还上调了每股收益预期，表示预计2024年不包括Opella在内的每股收益按恒定汇率计算至少将增长低个位数百分比。","market":"us","thumbnail":"https://community-static.tradeup.com/news/ae91103f9636ad1491772cb329b87218","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/ae91103f9636ad1491772cb329b87218"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1196649.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4007","IE00BFXG1179.USD","BK4585","SNY"],"gpt_icon":1},{"id":"2477044709","title":"CD&R与法国政府达成协议 接近完成收购赛诺菲消费健康业务交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2477044709","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477044709?lang=zh_cn&edition=full","pubTime":"2024-10-21 08:45","pubTimestamp":1729471500,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据知情人士透露，美国私募股权巨头Clayton Dubilier & Rice即将达成收购赛诺菲消费健康业务Opella控股权的协议，此前前者已与法国政府签署了社会承诺。知情人士透露，CD&R周日晚间与法国政府就与Opella相关的当地就业、投资和生产等方面的承诺达成了一致。法国财政部表示，将于周一上午在巴黎召开新闻发布会，讨论政府就赛诺菲计划将该业务控股权出售给 CD&R 所获得的担保。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410210851079f5264ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410210851079f5264ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SNY","BK4585","IE00BFXG1179.USD","BK4588"],"gpt_icon":0},{"id":"2476135011","title":"传CD&R收购赛诺菲(SNY.US)子公司获22家银行融资支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2476135011","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476135011?lang=zh_cn&edition=full","pubTime":"2024-10-17 10:21","pubTimestamp":1729131687,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据报道，私募股权巨头Clayton Dubilier & Rice 将以约150亿欧元的价格收购赛诺菲消费者健康部门Opella的股份，包括高盛集团和花旗集团在内的22家银行将为这笔交易提供融资。知情人士透露，预计贷款机构将在未来几天签署协议，提供86.5亿欧元的欧元和美元贷款和债券融资。由于众多银行争相参与，融资费用有望缩减。知情人士表示，七家银行中最多有四家可能负责欧元定期贷款，而其他全球协调人可能单独负责其余债券的出售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SNY","BK4007","BK4588","161121","BK4585","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2475599038","title":"赛诺菲(SNY.US)陷罢工风波!160亿美元Opella出售案引法国政府介入","url":"https://stock-news.laohu8.com/highlight/detail?id=2475599038","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475599038?lang=zh_cn&edition=full","pubTime":"2024-10-16 21:40","pubTimestamp":1729086052,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，法国工会组织了赛诺菲的工人，计划从周四开始罢工，以抗议该公司打算出售其消费者健康部门Opella，这笔交易价值约160亿美元。此前，赛诺菲已开始与美国私募股权公司Clayton Dubilier & Rice谈判，出售Opella的50%控股权。巴克莱报告指出，监管机构的担忧对赛诺菲股价造成了冲击，公司在下周公布第三季度业绩时将面临公布明确计划的压力。这表明，赛诺菲需要在满足政府要求和缓解市场担忧方面做出平衡，以确保交易的顺利进行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1195043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","SNY","BK4007","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2475354412","title":"传法国政府出手干预 私募巨头CD&R收购赛诺菲(SNY.US)消费者健康部门或受阻","url":"https://stock-news.laohu8.com/highlight/detail?id=2475354412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475354412?lang=zh_cn&edition=full","pubTime":"2024-10-14 18:50","pubTimestamp":1728903000,"startTime":"0","endTime":"0","summary":"据知情人士透露，法国政府正在考虑一些选择，包括国有投资银行法国银行收购赛诺菲旗下的消费者健康部门Opella的股份。智通财经APP此前报道称，私募股权巨头Clayton Dubilier & Rice即将以约150亿欧元的价格收购赛诺菲消费者健康部门Opella。赛诺菲在过去一年中努力拆分其消费者健康业务的高潮，公司旨在集中资源于尖端疗法领域，特别是在免疫学和疫苗方面，以创造长期价值。CD&R去年筹集了创纪录的260亿美元收购基金，并在法国市场表现活跃。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1193612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BFXG1179.USD","BK4007","BK4588","BK4585","SNY"],"gpt_icon":0},{"id":"2474707125","title":"传私募巨头CD&R拟164亿美元收购赛诺菲消费者健康部门","url":"https://stock-news.laohu8.com/highlight/detail?id=2474707125","media":"智通财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474707125?lang=zh_cn&edition=full","pubTime":"2024-10-11 08:25","pubTimestamp":1728606339,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，私募股权巨头Clayton Dubilier & Rice即将以约150亿欧元的价格收购赛诺菲旗下的消费者健康部门Opella，这笔交易有望成为今年欧洲最大的交易之一。据知情人士透露，CD&R在竞购中击败了对手PAI Partners，双方可能在未来几天宣布这一消息。赛诺菲及CD&R和PAI Partners的代表均未对此事发表评论。CD&R去年筹集了创纪录的260亿美元收购基金，并在法国市场表现活跃。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/d4b64489a6e4152e0e0e2be77f45f0e9","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/d4b64489a6e4152e0e0e2be77f45f0e9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1192696.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"传私募巨头CD&R拟164亿美元收购赛诺菲消费者健康部门","news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BFXG1179.USD","BK4588","BK4585","BK4007","SNY"],"gpt_icon":1},{"id":"2469496271","title":"赛诺菲(SNY.US)消费者健康部门争夺战升温 贷方准备超100亿欧元资金支持竞购","url":"https://stock-news.laohu8.com/highlight/detail?id=2469496271","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469496271?lang=zh_cn&edition=full","pubTime":"2024-09-24 21:10","pubTimestamp":1727183400,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，作为今年最受期待的收购案之一，银行和其他贷方正准备提供超过 100 亿欧元资金来支持对赛诺菲消费者健康部门的收购，目前该交易已进入最后阶段。知情人士透露，一些核心银行在周末签署了75亿至78亿欧元优先债务的融资承诺，以支持对此次收购的出价。智通财经APP在7月的报道显示，其中一些收购方建议对该部门的估值高达150亿欧元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1186649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BFXG1179.USD","SNY","BK4007","BK4585","BK4588"],"gpt_icon":0},{"id":"2469349804","title":"赛诺菲(SNY)CEO：相信公司有望通过多种新药实现增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2469349804","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469349804?lang=zh_cn&edition=full","pubTime":"2024-09-24 20:29","pubTimestamp":1727180945,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据媒体，赛诺菲(SNY)赛诺菲首席执行官Paul Hudson周一在接受采访时表示，公司有望通过多种新药实现强劲增长，而且不会像一些竞争对手那样面临畅销产品即将到期且成本高昂的问题。该公司在免疫学和疫苗领域拥有12项潜在的重磅资产，并且在本世纪末之前没有重大专利到期。该公司尚未涉足利润丰厚的肥胖药物市场，Hudson表示，赛诺菲不想创造制造Ozempic或 Mounjaro这些GLP-1药物的“仿制版”，“我们内部有一些未披露的项目，正在对有机会的第三方进行投资。”对于消费者医疗保健部门Opella，Hudson表示，正在考虑分拆、出售该部门或将其IPO。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"280213","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY","IE00BFXG1179.USD","BK4585","BK4588","BK4007"],"gpt_icon":0},{"id":"2469646814","title":"市场消息：贷款机构准备超过100亿欧元资金以支持赛诺菲(SNY.O)健康部门的收购。","url":"https://stock-news.laohu8.com/highlight/detail?id=2469646814","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469646814?lang=zh_cn&edition=full","pubTime":"2024-09-24 19:23","pubTimestamp":1727177010,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK5011","EUO","IE00BFXG1179.USD","BK4588","SNY","BK4585","BK4007","FXE","EURmain","MEURmain","0O59.UK"],"gpt_icon":0},{"id":"2468840643","title":"赛诺菲(SNY.US)BTK抑制剂Tolebrutinib有效延缓MS患者残疾进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2468840643","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468840643?lang=zh_cn&edition=full","pubTime":"2024-09-20 18:17","pubTimestamp":1726827422,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲周五在哥本哈根召开的一个研究大会上的一项晚期试验数据显示，其BTK抑制剂Tolebrutinib可将非复发继发性进行性多发性硬化症患者的残疾进展延缓31%。该公司在9月2日发布公告称，Tolebrutinib在HERCULES III期研究中达到主要终点——与安慰剂相比，该药物可以有效延缓残疾进展。赛诺菲计划在今年向全球监管机构提交该药物。不过，试验显示，接受Tolebrutinib治疗的患者不良事件略多，最令人担忧的是肝酶升高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1185309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0106831901.USD","LU1074936037.SGD","BK4007","LU1668664300.SGD","SNY","LU1363072403.SGD","LU2357305700.SGD","LU0225283273.USD","BK4585","LU0320765646.SGD","LU1989772923.USD","LU1720051017.SGD","BK4534","LU0971096721.USD","LU0098860793.USD","IE00BFXG1179.USD","LU1989772840.SGD","BK4127","BK4581","IE00BKVL7J92.USD","BK4504","LU1162221912.USD","IE00BZ1G4Q59.USD","LU0267386448.USD","LU1720051108.HKD","LU0314104364.USD","BK4588","LU1548497426.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sanofi.com","stockEarnings":[{"period":"1week","weight":-0.0653},{"period":"1month","weight":-0.1188},{"period":"3month","weight":-0.1128},{"period":"6month","weight":-0.0144},{"period":"1year","weight":0.035},{"period":"ytd","weight":-0.0354}],"compareEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.1063},{"period":"1year","weight":0.301},{"period":"ytd","weight":0.2324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sanofi于1994年根据法国法律注册成立。该公司是一家全球领先的医疗保健公司，专注于患者需求并从事治疗解决方案的研究、开发、制造和营销。该公司的活动围绕以下类别组织：DUPIXENT、神经病学&免疫学、罕见病、肿瘤学、罕见血液病、普药核心资产和非核心资产、疫苗、CHC。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.022852},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.021195},{"month":3,"riseRate":0.818182,"avgChangeRate":0.033135},{"month":4,"riseRate":0.681818,"avgChangeRate":0.026182},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.000457},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.014468},{"month":7,"riseRate":0.5,"avgChangeRate":0.018684},{"month":8,"riseRate":0.478261,"avgChangeRate":-0.011185},{"month":9,"riseRate":0.565217,"avgChangeRate":0.010124},{"month":10,"riseRate":0.521739,"avgChangeRate":-0.00342},{"month":11,"riseRate":0.608696,"avgChangeRate":-0.002233},{"month":12,"riseRate":0.727273,"avgChangeRate":0.03338}],"exchange":"NASDAQ","name":"赛诺菲安万特","nameEN":"Sanofi SA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛诺菲安万特,SNY,赛诺菲安万特股票,赛诺菲安万特股票老虎,赛诺菲安万特股票老虎国际,赛诺菲安万特行情,赛诺菲安万特股票行情,赛诺菲安万特股价,赛诺菲安万特股市,赛诺菲安万特股票价格,赛诺菲安万特股票交易,赛诺菲安万特股票购买,赛诺菲安万特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛诺菲安万特(SNY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛诺菲安万特(SNY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}